PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15448709-11	2004	Our data demonstrates that high glucose-induced upregulation of FN messenger RNA and protein levels occur via activation of MAPK/ERK pathway, which was prevented by treatment of cells with bosentan, PD098059 and PKC blocker chelerythrine.	Bosentan	189-197	fibronectin 1	Homo sapiens	64-66	
12582013-5	2003	Increased FN expression was shown to be dependent on ET receptor-mediated signaling, as the increase was prevented by the dual ET receptor antagonist bosentan.	Bosentan	150-158	fibronectin 1	Homo sapiens	10-12	
24015303-10	2013	Bosentan dose-dependently reduced the stimulatory effect of ET-1 on collagen type-I and fibronectin, but had no effect on TGF-beta1.	Bosentan	0-8	fibronectin 1	Homo sapiens	60-99	
16741042-8	2006	Diabetes increased FN and ED-B FN in all three organs, which was prevented by ET antagonist bosentan.	Bosentan	92-100	fibronectin 1	Homo sapiens	26-30	
11744810-12	2002	Bosentan prevented increased fibronectin and collagen alpha2(IV) mRNA expression, increased mesangial matrix deposition and GBM thickening.	Bosentan	0-8	fibronectin 1	Homo sapiens	29-40	
8823303-9	1996	Bosentan reduced levels of type I collagen and cellular fibronectin mRNAs in whole-liver tissue extracts in both models.	Bosentan	0-8	fibronectin 1	Homo sapiens	56-67